Neuraly is a startup biotech company.
Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine. Following the acquisition of exclusive licenses to patents covering the composition of matter and methods of use, research supporting the development of NLY01 was recently published in Nature Medicine1. These data demonstrated the critical role of the glial compartment of the neural tissue in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 18, 2018 | Series A | $36M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Geon Investment | — | Series A |